0.307

5.65% -0.0184

After Hours: .30 -0.007 -2.28%

Fibrogen Inc (FGEN)

Overview News Price History Option Chain Financials Why FGEN Down? Discussions Forecast

Fibrogen Inc stock is traded at $0.307, with a volume of 1.16M. It is down -5.65% in the last 24 hours and down -16.28% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Previous Close:

$0.3254

Open:

$0.3254

24h Volume:

1.16M

Relative Volume:

0.95

Market Cap:

$30.82M

Revenue:

$147.75M

Net Income/Loss:

$-284.23M

P/E Ratio:

-0.0906

EPS:

-3.39

Net Cash Flow:

$-317.54M

1W Performance:

+0.26%

1M Performance:

-16.28%

6M Performance:

-73.07%

1Y Performance:

-52.58%

1-Day Range:

$0.3013

$0.3254

1-Week Range:

$0.29

$0.3352

52-Week Range:

$0.29

$2.93

Fibrogen Inc Stock (FGEN) Company Profile

Name

Fibrogen Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

415-978-1200

Address

409 ILLINOIS STREET, SAN FRANCISCO, CA

Employee

486

Twitter

@FibroGenInc

Next Earnings Date

2024-11-04

Latest SEC Filings

FGEN's Discussions on Twitter

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy
Sep-22-21	Downgrade	Goldman	Neutral → Sell
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral
Jul-16-21	Downgrade	Stifel	Buy → Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-07-21	Downgrade	Mizuho	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy
Mar-02-21	Downgrade	Jefferies	Buy → Hold
Feb-01-21	Initiated	H.C. Wainwright	Buy
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy
May-01-20	Initiated	Cowen	Market Perform
Apr-27-20	Initiated	BofA/Merrill	Neutral
May-29-19	Resumed	Goldman	Neutral
May-10-19	Downgrade	William Blair	Outperform → Mkt Perform
Apr-12-19	Initiated	Piper Jaffray	Neutral
Feb-11-19	Resumed	Stifel	Buy
Dec-19-18	Upgrade	Citigroup	Neutral → Buy
Aug-08-17	Reiterated	Leerink Partners	Outperform
Aug-08-17	Reiterated	Stifel	Buy
Jul-21-17	Downgrade	Goldman	Buy → Neutral
Jul-11-17	Initiated	Jefferies	Buy
Feb-11-16	Upgrade	Credit Suisse	Neutral → Outperform
Jan-21-16	Initiated	Credit Suisse	Neutral
Dec-04-15	Initiated	Citigroup	Buy
Sep-23-15	Initiated	Lake Street	Hold
Jul-29-15	Initiated	Citigroup	Buy
Jul-20-15	Upgrade	Goldman	Neutral → Buy
Dec-09-14	Initiated	Stifel	Buy

View All

Fibrogen Inc Stock (FGEN) Latest News

Nov 04, 2024

FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire

Nov 04, 2024

Oct 31, 2024

Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register

Oct 31, 2024

Oct 29, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Oct 29, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St

Oct 29, 2024

FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World

Oct 29, 2024

Oct 28, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 21, 2024

FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World

Oct 21, 2024

Oct 16, 2024

The growth track for FibroGen Inc (FGEN) has changed recently - SETE News

Oct 16, 2024

Oct 15, 2024

Should investors be concerned about FibroGen Inc (FGEN)? - US Post News

Oct 15, 2024

Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 15, 2024

Oct 14, 2024

Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex

Oct 14, 2024

Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024

Oct 12, 2024

Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 12, 2024

Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World

Oct 12, 2024

Oct 11, 2024

FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St

Oct 11, 2024

Oct 10, 2024